## Supplementary Table 3. Distribution of Clinical Variables by RT dose

~J 212 4000		N (%)				
Variable	Level	Total	<=66Gy	>66Gy	P Value	
		44 (23,				
Age	Median(Range)	50)	44 (23,50)	43(28,50)	0.4849	
		86				
RSI_Subtype	Sensitive	(25.1%) 173	59 (24.4%)	27 (27%)	0.8859	
	Intermediate	(50.6%) 83	124 (51.2%)	49 (49%)		
	Resistant	(24.3%)	59 (24.4%)	24 (24%)		
	Total	342	242 (70.8%)	100 (29.2%)		
Origin	Dutch	147 (43%)	105 (43.4%)	42 (42%)	0.9088	
origin.	French	195 (57%)	137 (56.6%)	58 (58%)	0.7000	
	Total	342	242 (70.8%)	100 (29.2%)		
		224				
Local Recurrence	No Recurrence	(65.5%)	152 (62.8%)	72 (72%)	0.1014	
_		118	,	,		
	Recurrence	(34.5%)	90 (37.2%)	28 (28%)		
	Total	342	242 (70.8%)	100 (29.2%)		
		215				
T stage	pT1	(63.2%) 125	158 (65.6%)	57 (57.6%)	0.1760	
	pT2-3	(36.8%)	83 (34.4%)	42 (42.4%)		
	Total	340	241 (70.9%)	99 (29.1%)		
		37				
Surgical Margin	positive	(11.2%) 293	13 (5.5%)	24 (26.1%)	<.0001	
	negative	(88.8%)	225 (94.5%)	68 (73.9%)		
	Total	330	238 (72.1%)	92 (27.9%)		
Surgical margin invasive	positive	21 (6.5%) 301	7 (3%)	14 (15.7%)	0.0002	
	negative	(93.5%)	226 (97%)	75 (84.3%)		
	Total	322	233 (72.4%)	89 (27.6%)		
Surgical margin DCIS	positive	8 (4.3%) 176	1 (0.7%)	7 (13.2%)	0.0009	
	negative	(94.1%)	131 (97.8%)	45 (84.9%)		
	unknown	3 (1.6%)	2 (1.5%)	1 (1.9%)		
	Total	187	134 (71.7%)	53 (28.3%)		
N stage	pN+	121 (36%)	76 (32.2%)	45 (45%)	0.0326	
•	pN-	215 (64%)	160 (67.8%)	55 (55%)		

	Total	336	236 (70.2%)	100 (29.8%)	
RT boost	boost	248 (72.5%) 94	148 (61.2%)	100 (100%)	<.0001
	no boost Total	(27.5%) 342	94 (38.8%) 242 (70.8%)	0 (0%) 100 (29.2%)	
Chemotherapy (CT)	CT	132 (38.7%) 209	83 (34.4%)	49 (49%)	0.0142
	no CT Total	(61.3%) 341	158 (65.6%) 241 (70.7%)	51 (51%) 100 (29.3%)	
Hormonal therapy (HT)	HT	31 (9.1%) 310	18 (7.5%)	13 (13%)	0.1481
	no HT Total	(90.9%) 341	223 (92.5%) 241 (70.7%)	87 (87%) 100 (29.3%)	
Histology shape	multinodular	16 (4.9%) 85	9 (3.9%)	7 (7.7%)	0.2439
	sharply demarcated	(26.2%) 223	65 (27.9%)	20 (22%)	
	stellate Total	(68.8%) 324	159 (68.2%) 233 (71.9%)	64 (70.3%) 91 (28.1%)	
***		291	202 (02 00)	00 (000)	0.555
Histology type	ductal lobular other type Total	(85.1%) 26 (7.6%) 25 (7.3%) 342	203 (83.9%) 19 (7.9%) 20 (8.3%) 242 (70.8%)	88 (88%) 7 (7%) 5 (5%) 100 (29.2%)	0.5557
		55			
Histology grade	I	(16.3%) 147	40 (16.7%)	15 (15.3%)	0.8956
	II	(43.5%) 136	105 (43.8%)	42 (42.9%)	
	III Total	(40.2%) 338	95 (39.6%) 240 (71%)	41 (41.8%) 98 (29%)	
Tubule formation	NA	9 (2.6%) 79	6 (2.5%)	3 (3%)	0.8611
	tubule50-90%	(23.1%) 234	58 (24%)	21 (21%)	
	tubule<10% tubule>90%	(68.4%) 20 (5.8%)	163 (67.4%) 15 (6.2%)	71 (71%) 5 (5%)	
	Total	342	242 (70.8%)	100 (29.2%)	
polymorphism	polymorph1	15 (4.5%) 131	13 (5.5%)	2 (2.1%)	0.1895
	polymorph2	(39.5%)	87 (37%)	44 (45.4%)	

	polymorph3 Total	186 (56%) 332	135 (57.4%) 235 (70.8%)	51 (52.6%) 97 (29.2%)	
Mitotic index	Mitotic 1 Mitotic 2 Mitotic 3 Total	174 (53%) 59 (18%) 95 (29%) 328	125 (53.6%) 42 (18%) 66 (28.3%) 233 (71%)	49 (51.6%) 17 (17.9%) 29 (30.5%) 95 (29%)	0.9331
DCIS inside	DCIS inside No DCIS inside Total	93 (38.1%) 151 (61.9%) 244	67 (38.5%) 107 (61.5%) 174 (71.3%)	26 (37.1%) 44 (62.9%) 70 (28.7%)	0.8824
DCIS outside	DCIS outside  No DCIS outside	75 (31.9%) 160 (68.1%)	51 (30%) 119 (70%)	24 (36.9%) 41 (63.1%)	0.3489
DOIG	Total	235	170 (72.3%)	65 (27.7%)	0.5204
DCIS	DCIS No DCIS Total	210 (64%) 118 (36%) 328	147 (62.8%) 87 (37.2%) 234 (71.3%)	63 (67%) 31 (33%) 94 (28.7%)	0.5204
DCIS Grade	DCIS high grade DCIS intermed grade	119 (57.2%) 69 (33.2%)	85 (58.2%) 44 (30.1%)	34 (54.8%) 25 (40.3%)	0.1703
	DCIS low grade Total	20 (9.6%)	17 (11.6%) 146 (70.2%)	3 (4.8%) 62 (29.8%)	
LCIS	LCIS present	31 (9.4%) 300	19 (8.1%)	12 (12.5%)	0.2173
	No LCIS Total	(90.6%) 331	216 (91.9%) 235 (71%)	84 (87.5%) 96 (29%)	
Lympho-vascular invasion	LVI present	11 (4.2%) 253	7 (3.5%)	4 (6.1%)	0.4750
	No LVI Total	(95.8%) 264	191 (96.5%) 198 (75%)	62 (93.9%) 66 (25%)	
LVI quadrant	1 LVI	11 (13.8%) 31	7 (14.9%)	4 (12.1%)	0.5567
	2-5 LVI	(38.8%) 38	20 (42.6%)	11 (33.3%)	
	>5 LVI Total	(47.5%) 80	20 (42.6%) 47 (58.8%)	18 (54.5%) 33 (41.3%)	
p53	p53+	24	14 (22.6%)	10 (28.6%)	0.6263

		(24.7%) 73			
	p53-	(75.3%)	48 (77.4%)	25 (71.4%)	
	Total	97	62 (63.9%)	35 (36.1%)	
		75			
ER status	0	(21.9%)	61 (25.2%)	14 (14%)	0.0273
	1	267 (78.1%)	181 (74.8%)	86 (86%)	
	Total	342	242 (70.8%)	100 (29.2%)	
		137			
PR status	0	(40.1%)	98 (40.5%)	39 (39%)	0.8064
		205		(5)	
	1 T-4-1	(59.9%)	144 (59.5%)	61 (61%)	
	Total	342	242 (70.8%)	100 (29.2%)	
		289			
Her-2-neu status	0	(84.5%) 53	200 (82.6%)	89 (89%)	0.1886
	1	(15.5%)	42 (17.4%)	11 (11%)	
	Total	342	242 (70.8%)	100 (29.2%)	
		173			
Proliferative index	0	(50.6%)	122 (50.4%)	51 (51%)	1.0000
	1	169	120 (40 60()	40 (400/)	
	1 Total	(49.4%) 342	120 (49.6%) 242 (70.8%)	49 (49%) 100 (29.2%)	
	Total	3-12	242 (70.070)	100 (27.270)	
Molecular subtype	HER2	14 (4.1%) 145	12 (5%)	2 (2%)	0.1008
	LUMA	(42.4%) 86	101 (41.7%)	44 (44%)	
	LUMB	(25.1%) 39	53 (21.9%)	33 (33%)	
	LUMHER	(11.4%)	30 (12.4%)	9 (9%)	
	TN Tatal	58 (17%)	46 (19%)	12 (12%)	
	Total	342	242 (70.8%)	100 (29.2%)	
Triple Negative (TN)	Not TN	284 (83%)	196 (81%)	88 (88%)	0.1533
	TNP	58 (17%)	46 (19%)	12 (12%)	
	Total	342	242 (70.8%)	100 (29.2%)	

P Value is calculated using Chi square test using exact method with Monte Carlo estimation.